Several other analysts also recently weighed in on TGTX. Zacks Investment Research raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 25th. Aegis initiated coverage on shares of TG Therapeutics in a research report on Wednesday, February 22nd. They set a “buy” rating and a $26.00 target price on the stock. FBR & Co reissued an “outperform” rating and set a $26.00 target price (up previously from $24.00) on shares of TG Therapeutics in a research report on Monday, March 6th. Langenberg & Company boosted their target price on shares of TG Therapeutics from $28.00 to $30.00 and gave the stock a “positive” rating in a research report on Tuesday, March 7th. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of TG Therapeutics in a research report on Tuesday, March 7th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $23.17.
TG Therapeutics Inc (NASDAQ:TGTX) – Equities research analysts at Jefferies Group upped their Q2 2017 EPS estimates for TG Therapeutics in a research note issued on Monday. Jefferies Group analyst M. Andrews now anticipates that the biopharmaceutical company will earn ($0.41) per share for the quarter, up from their prior forecast of ($0.42). Jefferies Group has a “Buy” rating and a $23.00 price objective on the stock. Jefferies Group also issued estimates for TG Therapeutics’ Q3 2017 earnings at ($0.43) EPS, Q4 2017 earnings at ($0.44) EPS, FY2017 earnings at ($1.79) EPS, FY2018 earnings at ($1.84) EPS, FY2019 earnings at ($1.98) EPS, FY2020 earnings at ($1.24) EPS and FY2021 earnings at ($0.55) EPS.
TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Friday, May 5th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.10. The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative return on equity of 83.18% and a negative net margin of 47,494.08%. Hedge funds have recently made changes to their positions in the stock. RA Capital Management LLC boosted its stake in shares of TG Therapeutics by 2.2% in the third quarter. RA Capital Management LLC now owns 4,631,114 shares of the biopharmaceutical company’s stock valued at $35,845,000 after buying an additional 99,400 shares during the last quarter. Baker BROS. Advisors LP acquired a new stake in shares of TG Therapeutics during the third quarter valued at approximately $15,511,000. Jennison Associates LLC acquired a new stake in shares of TG Therapeutics during the first quarter valued at approximately $16,034,000. Columbus Circle Investors boosted its stake in shares of TG Therapeutics by 29.3% in the first quarter. Columbus Circle Investors now owns 1,004,421 shares of the biopharmaceutical company’s stock valued at $11,702,000 after buying an additional 227,722 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of TG Therapeutics by 6.7% in the fourth quarter. State Street Corp now owns 679,115 shares of the biopharmaceutical company’s stock valued at $3,157,000 after buying an additional 42,760 shares during the last quarter. Institutional investors and hedge funds own 50.08% of the company’s stock.
In other TG Therapeutics news, Director Laurence N. Charney sold 7,000 shares of TG Therapeutics stock in a transaction that occurred on Tuesday, April 4th. The shares were sold at an average price of $11.17, for a total transaction of $78,190.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director William James Kennedy sold 8,548 shares of TG Therapeutics stock in a transaction that occurred on Tuesday, April 11th. The shares were sold at an average price of $10.27, for a total transaction of $87,787.96. The disclosure for this sale can be found here. Insiders own 19.00% of the company’s stock. About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.